IE58638B1 - A tumor therapeutic agent and a process for its preparation - Google Patents
A tumor therapeutic agent and a process for its preparationInfo
- Publication number
- IE58638B1 IE58638B1 IE219185A IE219185A IE58638B1 IE 58638 B1 IE58638 B1 IE 58638B1 IE 219185 A IE219185 A IE 219185A IE 219185 A IE219185 A IE 219185A IE 58638 B1 IE58638 B1 IE 58638B1
- Authority
- IE
- Ireland
- Prior art keywords
- therapeutic agent
- treatment
- cells
- preparation
- nca
- Prior art date
Links
- 239000003814 drug Substances 0.000 title claims abstract description 16
- 229940124597 therapeutic agent Drugs 0.000 title claims abstract description 16
- 238000000034 method Methods 0.000 title claims abstract description 10
- 238000002360 preparation method Methods 0.000 title claims description 5
- 206010028980 Neoplasm Diseases 0.000 title description 9
- 239000000427 antigen Substances 0.000 claims abstract description 14
- 102000036639 antigens Human genes 0.000 claims abstract description 14
- 108091007433 antigens Proteins 0.000 claims abstract description 14
- 210000004881 tumor cell Anatomy 0.000 claims abstract description 11
- 102000005348 Neuraminidase Human genes 0.000 claims abstract description 7
- 108010006232 Neuraminidase Proteins 0.000 claims abstract description 7
- 239000000126 substance Substances 0.000 claims abstract description 6
- 201000010099 disease Diseases 0.000 claims description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 10
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 239000002671 adjuvant Substances 0.000 claims description 4
- 230000028993 immune response Effects 0.000 claims description 4
- 239000012528 membrane Substances 0.000 claims description 4
- 238000004108 freeze drying Methods 0.000 claims description 3
- 230000006641 stabilisation Effects 0.000 claims description 3
- 238000011105 stabilization Methods 0.000 claims description 3
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 210000005260 human cell Anatomy 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 28
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 10
- 239000002953 phosphate buffered saline Substances 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 239000013049 sediment Substances 0.000 description 7
- 102100025473 Carcinoembryonic antigen-related cell adhesion molecule 6 Human genes 0.000 description 6
- 101000914326 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 6 Proteins 0.000 description 6
- 229960005486 vaccine Drugs 0.000 description 6
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000002255 vaccination Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 239000012980 RPMI-1640 medium Substances 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 239000012894 fetal calf serum Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 2
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 2
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 2
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 2
- 239000001099 ammonium carbonate Substances 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 230000001588 bifunctional effect Effects 0.000 description 2
- 239000012620 biological material Substances 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 229960004857 mitomycin Drugs 0.000 description 2
- 229910052709 silver Inorganic materials 0.000 description 2
- 239000004332 silver Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- ZNZYKNKBJPZETN-WELNAUFTSA-N Dialdehyde 11678 Chemical compound N1C2=CC=CC=C2C2=C1[C@H](C[C@H](/C(=C/O)C(=O)OC)[C@@H](C=C)C=O)NCC2 ZNZYKNKBJPZETN-WELNAUFTSA-N 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 150000001844 chromium Chemical class 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000010908 decantation Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- -1 for example Substances 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 125000001841 imino group Chemical group [H]N=* 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 150000002513 isocyanates Chemical class 0.000 description 1
- 150000002540 isothiocyanates Chemical class 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 238000007694 polyacrylamide gel isoelectric focusing Methods 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 210000001768 subcellular fraction Anatomy 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 description 1
- 229940033123 tannic acid Drugs 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Diaphragms For Electromechanical Transducers (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
- Window Of Vehicle (AREA)
- Peptides Or Proteins (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19843432714 DE3432714A1 (de) | 1984-09-06 | 1984-09-06 | Tumortherapeutikum und verfahren zu seiner herstellung |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IE852191L IE852191L (en) | 1986-03-06 |
| IE58638B1 true IE58638B1 (en) | 1993-10-20 |
Family
ID=6244749
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IE219185A IE58638B1 (en) | 1984-09-06 | 1985-09-05 | A tumor therapeutic agent and a process for its preparation |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP0173951B1 (forum.php) |
| JP (1) | JPS6168427A (forum.php) |
| AT (1) | ATE64531T1 (forum.php) |
| CA (1) | CA1277600C (forum.php) |
| DE (2) | DE3432714A1 (forum.php) |
| DK (1) | DK172253B1 (forum.php) |
| ES (1) | ES8704082A1 (forum.php) |
| FI (1) | FI88360C (forum.php) |
| GR (1) | GR852149B (forum.php) |
| IE (1) | IE58638B1 (forum.php) |
| IL (1) | IL76289A (forum.php) |
| PT (1) | PT81093B (forum.php) |
| ZA (1) | ZA856807B (forum.php) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3806565A1 (de) * | 1988-03-01 | 1989-09-14 | Deutsches Krebsforsch | Virusmodifizierte tumorvakzinen fuer die immuntherapie von tumormetastasen |
| AT398900B (de) * | 1991-02-12 | 1995-02-27 | Pekar Rudolf Dr | Vakzine für eine immuntherapie |
| US7070782B1 (en) | 1992-11-05 | 2006-07-04 | Sloan-Kettering Institute For Cancer Research | Prostate-specific membrane antigen |
| US6953668B1 (en) | 1992-11-05 | 2005-10-11 | Sloan-Kettering Institute For Cancer Research | Prostate-specific membrane antigen |
| US7105159B1 (en) | 1992-11-05 | 2006-09-12 | Sloan-Kettering Institute For Cancer Research | Antibodies to prostate-specific membrane antigen |
| DE69334071T2 (de) * | 1992-11-05 | 2007-10-25 | Sloan-Kettering Institute For Cancer Research | Prostata-spezifisches membranantigen |
| WO1996026272A1 (en) | 1995-02-24 | 1996-08-29 | Sloan-Kettering Institute For Cancer Research | Prostate-specific membrane antigen and uses thereof |
| US6569432B1 (en) | 1995-02-24 | 2003-05-27 | Sloan-Kettering Institute For Cancer Research | Prostate-specific membrane antigen and uses thereof |
| DE19506483A1 (de) * | 1995-02-24 | 1996-08-29 | Jens Dr Dr Atzpodien | Lyophilisat-Vakzine |
| US20050215472A1 (en) | 2001-10-23 | 2005-09-29 | Psma Development Company, Llc | PSMA formulations and uses thereof |
| JP5355839B2 (ja) | 2001-10-23 | 2013-11-27 | ピーエスエムエー デベロプメント カンパニー， エル．エル．シー． | Ｐｓｍａ抗体およびタンパク質マルチマー |
| CN1315536C (zh) * | 2002-09-13 | 2007-05-16 | 李进 | 肿瘤抗原疫苗及其制备方法和疫苗组合物 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4152410A (en) * | 1975-09-03 | 1979-05-01 | Eisai Co., Ltd. | Diagnosis reagent for neoplasm and method for diagnosis of neoplasm |
| DE2643215A1 (de) * | 1976-09-25 | 1978-04-06 | Bayer Ag | Cancerostatisch wirksame praeparationen aus tumorzellen und ein verfahren zu ihrer herstellung |
| ZA776822B (en) * | 1976-11-24 | 1979-06-27 | D Mccollester | Vaccine and method for immunotherapy of neoplastic disease |
| DE2918927A1 (de) * | 1979-05-10 | 1980-11-20 | Hans Prof Dr Limburg | Arzneipraeparat zur behandlung von carcinomen und verfahren zu dessen herstellung |
| US4446122A (en) * | 1979-12-28 | 1984-05-01 | Research Corporation | Purified human prostate antigen |
| US4468457A (en) * | 1981-06-01 | 1984-08-28 | David M. Goldenberg | Method for producing a CSAp tryptic peptide and anti-CSAp antibodies |
| DE3329184A1 (de) * | 1983-08-12 | 1985-02-21 | Behringwerke Ag, 3550 Marburg | Monoklonale antikoerper mit spezifitaet fuer membran-assoziierte antigene |
| DE3416774A1 (de) * | 1984-05-07 | 1985-11-14 | Behringwerke Ag, 3550 Marburg | Monoklonale antikoerper, verfahren zu ihrer herstellung sowie ihre verwendung |
-
1984
- 1984-09-06 DE DE19843432714 patent/DE3432714A1/de not_active Withdrawn
-
1985
- 1985-08-27 DE DE8585110757T patent/DE3583265D1/de not_active Expired - Lifetime
- 1985-08-27 EP EP85110757A patent/EP0173951B1/de not_active Expired - Lifetime
- 1985-08-27 AT AT85110757T patent/ATE64531T1/de not_active IP Right Cessation
- 1985-09-03 DK DK402485A patent/DK172253B1/da not_active IP Right Cessation
- 1985-09-04 IL IL76289A patent/IL76289A/xx not_active IP Right Cessation
- 1985-09-04 FI FI853389A patent/FI88360C/fi not_active IP Right Cessation
- 1985-09-04 ES ES546701A patent/ES8704082A1/es not_active Expired
- 1985-09-04 GR GR852149A patent/GR852149B/el unknown
- 1985-09-05 IE IE219185A patent/IE58638B1/en not_active IP Right Cessation
- 1985-09-05 CA CA000490026A patent/CA1277600C/en not_active Expired - Lifetime
- 1985-09-05 JP JP60195000A patent/JPS6168427A/ja active Pending
- 1985-09-05 ZA ZA856807A patent/ZA856807B/xx unknown
- 1985-09-05 PT PT81093A patent/PT81093B/pt not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| DE3432714A1 (de) | 1986-04-24 |
| GR852149B (forum.php) | 1986-01-03 |
| DK402485A (da) | 1986-03-07 |
| FI88360B (fi) | 1993-01-29 |
| ATE64531T1 (de) | 1991-07-15 |
| DE3583265D1 (de) | 1991-07-25 |
| FI88360C (fi) | 1993-05-10 |
| ES8704082A1 (es) | 1987-03-16 |
| CA1277600C (en) | 1990-12-11 |
| PT81093A (de) | 1985-10-01 |
| EP0173951A3 (en) | 1988-06-08 |
| EP0173951B1 (de) | 1991-06-19 |
| FI853389A0 (fi) | 1985-09-04 |
| ZA856807B (en) | 1986-04-30 |
| DK402485D0 (da) | 1985-09-03 |
| JPS6168427A (ja) | 1986-04-08 |
| PT81093B (pt) | 1988-07-01 |
| IL76289A0 (en) | 1986-01-31 |
| DK172253B1 (da) | 1998-02-09 |
| ES546701A0 (es) | 1987-03-16 |
| IE852191L (en) | 1986-03-06 |
| FI853389L (fi) | 1986-03-07 |
| IL76289A (en) | 1992-01-15 |
| EP0173951A2 (de) | 1986-03-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Springer et al. | Brief communication: Blood group MN antigens and precursors in normal and malignant human breast glandular tissue | |
| Fuks et al. | Carcinoembryonic antigen (CEA): Molecular biology and clinical significance | |
| Baldwin et al. | Blocking of lymphocyte-mediated cytotoxicity for rat hepatoma cells by tumour-specific antigen-antibody complexes | |
| Lewis et al. | Immunological studies in nephrotic syndrome associated with extrarenal malignant disease | |
| US6197298B1 (en) | Modified binding molecules specific for T lymphocytes and their use as in vivo immune modulators in animals | |
| EP0678744B1 (en) | Method for detecting urinary tumor associated antigens | |
| IE58638B1 (en) | A tumor therapeutic agent and a process for its preparation | |
| Alford et al. | Delayed cutaneous hypersensitivity reactions to extracts of malignant and normal breast cells | |
| US4758549A (en) | Lymphokine, monoclonal antibody specific to the lymphokine and their production and uses | |
| Yoshiike et al. | Epidermolysis bullosa acquisita antigen: relationship between the collagenase-sensitive and-insensitive domains | |
| US5030564A (en) | Monoclonal antibody specific to the lymphokine LK 2 and its method of production | |
| US6294172B1 (en) | Monoclonal antibodies with specificity for membrane-associated antigens | |
| NL8302484A (nl) | Interferon-preparaat en werkwijze voor de bereiding daarvan. | |
| Sinclair et al. | Regulation of the immune response: VIII. Characteristics of antibody-mediated suppression of an in vitro cell-mediated immune response | |
| Hirai et al. | Purification of specific antibody to α-foetoprotein and its immunological effect on cancer cells | |
| Suzuki et al. | Restoration Of Antigenicity Of Tissue Antigens, Cell‐Bound Immunoglobulins And Immune Deposits In Paraffin‐Embedded Tissue The Influence Of Fixation And Proteolytic Enzymatic Digestion | |
| Saya et al. | Derivation of a brain tumor-selective monoclonal antibody from hybridoma between mouse myeloma and rat spleen cells immune to syngeneic glioma | |
| WEISLOW et al. | Partial purification of a placental interferon with atypical characteristics | |
| US20040247589A1 (en) | Anti-tumor activity from reptile serum | |
| Daly et al. | Immunological and cultural characteristics of urothelium | |
| DE3784364D1 (de) | Tumorassoziiertes antigen. | |
| Eraizer et al. | Antigen expressed alternatively to α-fetoprotein of rat hepatomas | |
| JPH03209334A (ja) | リンパ腫またはその類似物の治療用医薬の製造に用いられる有効成分 | |
| Feye et al. | Auto-antibody to kidney tubular cells during retrograde chronic pyelonephritis in rats | |
| Tax et al. | Immunological Analysis of A Strain Mice Bearing the A-10 Mammary Adenocarcinoma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Patent lapsed |